<DOC>
	<DOCNO>NCT00543725</DOCNO>
	<brief_summary>The purpose trial compare effectiveness , safety tolerability TMC278 give dose 25 mg daily versus efavirenz ( EFV ) dose 600 mg daily , combine background regimen contain 2 nucleoside/nucleotide reverse transcriptase inhibitor ( investigator choice ABC/3TC , TDF/FTC AZT/3TC ) HIV-1 infected patient yet take anti-HIV drug . The following evaluation do : antiviral activity , immunologic change , viral geno-/phenotype evolution , relationship Pharmacokinetics ( PK ) PK/Pharmacodynamics Medical resource utilization treatment adherence .</brief_summary>
	<brief_title>TMC278-TiDP6-C215 : A Clinical Trial Treatment Naive HIV-subjects Patients Comparing TMC278 Efavirenz Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors</brief_title>
	<detailed_description>Over past decade , anti-human immunodeficiency virus ( HIV ) drug introduce sequentially use clinic . Currently , patient routinely treat 3 4 drug combination include nucleoside/tide analogue reverse transcriptase inhibitor ( NRTIs/NtRTIs ) , non-nucleoside reverse transcriptase inhibitor ( NNRTIs ) , protease inhibitor ( PIs ) , and/or fusion inhibitor . New potent antiretroviral ( ARV ) compound work people whose HIV-1 virus resistant available drug urgently need . This Phase III , randomize ( study medication assign chance ) , double-blind ( neither study physician patient know name study assign medication ) , double-dummy , active-controlled trial compare effectiveness , safety , ability tolerate TMC278 versus efavirenz ( EFV ) . The study last 104 week include screening period 4 week , 96-week treatment period , follow 4 week follow-up period . Patients randomly assign ( like toss coin ) TMC278 efavirenz combination two anti-HIV drug class nucleoside/nucleotide reverse transcriptase inhibitor . The hypothesis provide study investigational drug TMC278 perform like efavirenz ( EFV ) term antiviral effectiveness ( i.e. , suppress plasma viral load level &lt; 50 HIV-1 RNA ( ribonucleic acid ) copies/mL , ARV-na√Øve HIV-infected patient . During trial , patient ' health monitor physical examination , interview ass health well , laboratory test blood urine sample . Experimental Group : One tablet TMC278 25 mg daily ; plus efavirenz ( EFV ) placebo ; plus 2 nucleoside/nucleotide reverse transcriptase inhibitor ; Control Group : One tablet Placebo daily look like TMC278 plus EFV 600 mg daily plus 2 nucleoside/nucleotide reverse transcriptase inhibitor 104 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Patient document HIV1 infection Patient never treat therapeutic HIV vaccine ARV drug prior screen Patient 's HIV1 plasma viral load screen &gt; 5,000 HIV1 RNA copies/mL ( assayed RNA PCR standard specimen procedure ) Patient 's virus sensitive 2 nucleoside/nucleotide reverse transcriptase inhibitor choose treatment Patient agree start ART baseline visit Patient HLAB*5701 negative case abacavir include patient 's treatment regimen . Previous use ANY ARV drug ANY length time Any document evidence NNRTI resistance associate mutation patient 's HIV Category C AIDS define illness , except , Stable Kaposi Sarcoma Wasting syndrome progressive Pneumocystis carinii pneumonia ( PCP ) consider cured Active TB Allergy hypersensitivity study background ARTs Specific grade 3 4 toxicity Kidney impairment : calculated creatinine clearance &lt; 50 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Antiretroviral</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS</keyword>
	<keyword>TMC278-C215</keyword>
	<keyword>TMC278-TiDP6-C215</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>